NCT07533357Not yet recruiting
Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma
A Prospective Study of Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have longer overall survival. The main question it aims to answer is: Whether precursor exhausted T cells (Tpex) in negative tumor-draining lymph nodes have better predictive efficacy for treatment response than PD-L1 CPS.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 158 (estimated)
- First submitted
- 5 Apr 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2029
- Lead sponsor
- Fudan University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07533357
What you commit to
- Study type: Observational
- Planned participants: 158
- From Apr 2026 to the primary completion date, Apr 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Esophageal perforation or hematemesis
- Any active autoimmune disease or a history of autoimmune disease
- Disease progression occurs within 3months after PD-1 immunotherapy.
- Allergic to macromolecular protein preparations, or to any of the ingredients in PD-1 inhibitors for injection.
- Uncontrolled heart diseases or clinical symptoms
- Congenital or acquired immunodeficiency (such as HIV infection); active hepatitis B (HBV-DNA≥104 copy number/ml) or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the detection limit of the analytical method); active tuberculosis.
Who the study is looking for
- Aged ≥18 years
- Histologically confirmed esophageal carcinoma
- Clinical stages IV based on the 8th AJCC TNM classification, or recurrent esophageal cancer
- plan to treated with PD-1 immunotherapy
- Eastern Cooperative Oncology Group(ECOG) performance status: 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.